News Perspectives

Shots Fight Cancer-Linked Virus 8 Years

A vaccine appears to protect against human papillomavirus (HPV) for 8 years, a new study finds. Human papillomavirus causes most cases of cervical cancer. This was a long-term follow-up to an earlier study. In the original study, more than 1,700 boys and girls were randomly assigned to receive the vaccine or placebo shots. Those who received the placebo were given the actual vaccine 2 years later. Researchers called this the catch-up group. In the first group, the average child was 12 when vaccinated. In the catch-up group, the average age was 15. Each person received 3 doses. Researchers were able to keep track of more than 1,600 of the original study group. This included 1,100 from the first vaccination group. After up to 8 years (average 6.8), the vast majority of this group had blood antibodies against HPV.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In